Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dezocine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 13/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 6/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.63 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dezocine SCHEMBL29811203 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL29682715 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL12720257 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL9685743 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL11874182 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL3072 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL11874190 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL1369581 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL21081189 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL25583319 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4001331-A | ANTIINFLAMMATORY, ANALGESIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-01-04 | — | — | US | claimed |
| US-20220259140-A1 | CRYSTAL FORM AND AMORPHOUS FORM OF DEZOCINE ANALOGUE HYDROCHLORIDE | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2022-08-18 | — | — | US | disclosed |
| EP-3401306-B1 | DEZOCINE ANALOGUE | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2020-09-30 | — | — | EP | disclosed |
| US-10414718-B2 | Dezocine analogue | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-09-17 | — | — | US | disclosed |
| EP-0840731-B1 | POLYCYCLIC ALCALOID-DERIVATIVES AS NMDA-RECEPTOR ANTAGONISTS | SHIRE BIOCHEM INC (CA) | 2001-10-10 | — | — | EP | disclosed |
| US-5990104-A | INHIBITING NMDA RECEPTOR ACTIVATION BY ADMINISTERING DERIVATIVES OF GIVEN FORMULA, SUCH AS 5,6,7,8,9,11,12-HEPTAHYDRO-3-HYDROXY-5-METHYL-10-THIA-5,11 -METHANOBENZOCYCLODECEN-13-AMINE (SULPHAZOCINE) | BIOCHEM PHARMA, INC. (CA) | 1999-11-23 | — | — | US | disclosed |
| US-4540806-A | Benzocycloalkane amines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414718-B2 | Dezocine analogue | DDO, DDC, DAO | OPRM1 9/4885OPRK1 93/4885OPRD1 359/4885 |
| US-20220259140-A1 | CRYSTAL FORM AND AMORPHOUS FORM OF DEZOCINE ANALOGUE HYDROCHLORIDE | DAZAP1, DEK, IDUA | OPRM1 13/4885OPRK1 73/4885OPRD1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.